Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286298052> ?p ?o ?g. }
- W4286298052 endingPage "10033" @default.
- W4286298052 startingPage "10033" @default.
- W4286298052 abstract "10033 Background: Low dose maintenance therapy as consolidation after multimodal standard therapy has been shown to improve survival in patients with sarcoma. It is however unclear which drugs and how long would be optimal. We investigated whether adding oral maintenance chemotherapy after standard multimodal therapy (ST) in patients with localized RMS and RMS-like sarcoma defined as high and very-high risk (HR and VHR), according to CWS stratification, would improve survival. Methods: Patients (pts) age > 6 months < 21 years, with 1. embryonal RMS N0, incompletely resected, (Group II or III), tumor size > 5cm and/or ≥10 years, in unfavorable primary sites and all N1 (HR RMS Group), 2. alveolar RMS N0/N1 (VHR RMS Group) 3.Unidfferentiated sarcoma (UDS), extraskeletal Ewing sarcoma (EES) and primary non resectable (Group III) synovial sarcoma (SS) (HR RMS-like Group) in complete remission after ST including 9 cycles of ifosfamide, vincristine and actinomycin D +/- doxorubicin, surgery and/or radiotherapy were eligible for randomization to stop treatment (S-arm) or receive maintenance chemotherapy (M-arm) with eight 10-days courses consisting of trofosfamide (2x 75mg/m²/day) and idarubicine (1 x 5mg/m²/day 1,4,7,10) alternating with trofosfamide and etoposide (2x 25mg/m²/day). The study was designed with 80% power and a two-sided alpha level of 5% to detect an increase in 3 yr EFS from 60 to 75%. Randomisation was stratified according to risk groups. To reduce possible imbalances in the number of treatment assignments, a permuted block design was used. The initial calculated sample size was 145 pts in each group (recruitment period six years). Due to the lower than planned recruitement rate, the accrual was extended to 10 years and sample size recalculated to 98 pts in each group. Results: Between 1.7.2009 and 30.6.2019, 441 pts were eligible at diagnosis and 337 at the end of ST. 195 pts were randomized: 99 were assigned to the S-arm and 96 to M-arm. The distribution of the following clinical features:age, gender, tumor size, IRS-Group, T-Status, N-Status, histology and localisation showed no significant difference between the treatment groups. In the intent to treat population, with a median follow up of 4.9 years (IQR 3.0-5.7) in surviving pts, 3yr EFS and OS in M-arm vs S-arm were respectively: EFS 66.2% (95% IC 57.1-76.79) vs 75.0% (95% IC 66.8-84.3) (p 0.07) and OS 81.9% (95% IC 74.2-90.4) vs 84.6 (95% IC 77.5-92.4) (p 0.15). Toxicity grade 3 (no grade 4) in the M-arm was: hematological in 51 %, febrile infection 5%, sensory neuropathy in 1% pts. Conclusions: The addition of maintenance therapy with trofosfamide, etoposide and idarubicine after ST does not improve EFS and OS in patients with high risk RMS and RMS-like sarcomas. Clinical trial information: 2007-0001478-10." @default.
- W4286298052 created "2022-07-21" @default.
- W4286298052 creator A5002564888 @default.
- W4286298052 creator A5008197312 @default.
- W4286298052 creator A5011059803 @default.
- W4286298052 creator A5016827658 @default.
- W4286298052 creator A5020975466 @default.
- W4286298052 creator A5027350146 @default.
- W4286298052 creator A5035626095 @default.
- W4286298052 creator A5037725633 @default.
- W4286298052 creator A5042718514 @default.
- W4286298052 creator A5042744031 @default.
- W4286298052 creator A5044138253 @default.
- W4286298052 creator A5055374270 @default.
- W4286298052 creator A5063765068 @default.
- W4286298052 creator A5065181259 @default.
- W4286298052 creator A5074367227 @default.
- W4286298052 creator A5082438382 @default.
- W4286298052 creator A5087280182 @default.
- W4286298052 creator A5088661807 @default.
- W4286298052 creator A5091832008 @default.
- W4286298052 date "2022-06-01" @default.
- W4286298052 modified "2023-10-14" @default.
- W4286298052 title "Metronomic oral maintenance chemotherapy in patients with localized high-risk rhabdomyosarcoma (RMS) and RMS-like tumors: A report from a randomized, multicenter, phase III trial CWS-2007HR." @default.
- W4286298052 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.10033" @default.
- W4286298052 hasPublicationYear "2022" @default.
- W4286298052 type Work @default.
- W4286298052 citedByCount "2" @default.
- W4286298052 countsByYear W42862980522023 @default.
- W4286298052 crossrefType "journal-article" @default.
- W4286298052 hasAuthorship W4286298052A5002564888 @default.
- W4286298052 hasAuthorship W4286298052A5008197312 @default.
- W4286298052 hasAuthorship W4286298052A5011059803 @default.
- W4286298052 hasAuthorship W4286298052A5016827658 @default.
- W4286298052 hasAuthorship W4286298052A5020975466 @default.
- W4286298052 hasAuthorship W4286298052A5027350146 @default.
- W4286298052 hasAuthorship W4286298052A5035626095 @default.
- W4286298052 hasAuthorship W4286298052A5037725633 @default.
- W4286298052 hasAuthorship W4286298052A5042718514 @default.
- W4286298052 hasAuthorship W4286298052A5042744031 @default.
- W4286298052 hasAuthorship W4286298052A5044138253 @default.
- W4286298052 hasAuthorship W4286298052A5055374270 @default.
- W4286298052 hasAuthorship W4286298052A5063765068 @default.
- W4286298052 hasAuthorship W4286298052A5065181259 @default.
- W4286298052 hasAuthorship W4286298052A5074367227 @default.
- W4286298052 hasAuthorship W4286298052A5082438382 @default.
- W4286298052 hasAuthorship W4286298052A5087280182 @default.
- W4286298052 hasAuthorship W4286298052A5088661807 @default.
- W4286298052 hasAuthorship W4286298052A5091832008 @default.
- W4286298052 hasConcept C126322002 @default.
- W4286298052 hasConcept C141071460 @default.
- W4286298052 hasConcept C142724271 @default.
- W4286298052 hasConcept C143998085 @default.
- W4286298052 hasConcept C168563851 @default.
- W4286298052 hasConcept C204243189 @default.
- W4286298052 hasConcept C2776694085 @default.
- W4286298052 hasConcept C2776755627 @default.
- W4286298052 hasConcept C2777506904 @default.
- W4286298052 hasConcept C2778119113 @default.
- W4286298052 hasConcept C2778256501 @default.
- W4286298052 hasConcept C2778283404 @default.
- W4286298052 hasConcept C2779429289 @default.
- W4286298052 hasConcept C2780844630 @default.
- W4286298052 hasConcept C31760486 @default.
- W4286298052 hasConcept C71924100 @default.
- W4286298052 hasConceptScore W4286298052C126322002 @default.
- W4286298052 hasConceptScore W4286298052C141071460 @default.
- W4286298052 hasConceptScore W4286298052C142724271 @default.
- W4286298052 hasConceptScore W4286298052C143998085 @default.
- W4286298052 hasConceptScore W4286298052C168563851 @default.
- W4286298052 hasConceptScore W4286298052C204243189 @default.
- W4286298052 hasConceptScore W4286298052C2776694085 @default.
- W4286298052 hasConceptScore W4286298052C2776755627 @default.
- W4286298052 hasConceptScore W4286298052C2777506904 @default.
- W4286298052 hasConceptScore W4286298052C2778119113 @default.
- W4286298052 hasConceptScore W4286298052C2778256501 @default.
- W4286298052 hasConceptScore W4286298052C2778283404 @default.
- W4286298052 hasConceptScore W4286298052C2779429289 @default.
- W4286298052 hasConceptScore W4286298052C2780844630 @default.
- W4286298052 hasConceptScore W4286298052C31760486 @default.
- W4286298052 hasConceptScore W4286298052C71924100 @default.
- W4286298052 hasIssue "16_suppl" @default.
- W4286298052 hasLocation W42862980521 @default.
- W4286298052 hasOpenAccess W4286298052 @default.
- W4286298052 hasPrimaryLocation W42862980521 @default.
- W4286298052 hasRelatedWork W1970473724 @default.
- W4286298052 hasRelatedWork W1984064387 @default.
- W4286298052 hasRelatedWork W2006022537 @default.
- W4286298052 hasRelatedWork W2027234160 @default.
- W4286298052 hasRelatedWork W2098772462 @default.
- W4286298052 hasRelatedWork W2133154453 @default.
- W4286298052 hasRelatedWork W2399446920 @default.
- W4286298052 hasRelatedWork W2483809848 @default.
- W4286298052 hasRelatedWork W2550878253 @default.
- W4286298052 hasRelatedWork W4290257576 @default.
- W4286298052 hasVolume "40" @default.
- W4286298052 isParatext "false" @default.
- W4286298052 isRetracted "false" @default.